While Beam Therapeutics Inc has overperformed by 2.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BEAM fell by -30.89%, with highs and lows ranging from $35.25 to $13.52, whereas the simple moving average fell by -26.28% in the last 200 days.
On March 28, 2025, BofA Securities Upgraded Beam Therapeutics Inc (NASDAQ: BEAM) to Buy. A report published by Scotiabank on March 10, 2025, Upgraded its rating to ‘Sector Outperform’ for BEAM. Leerink Partners November 06, 2024d the rating to Outperform on November 06, 2024, and set its price target from $27 to $39. Scotiabank initiated its ‘Sector Outperform’ rating for BEAM, as published in its report on October 16, 2024. H.C. Wainwright’s report from July 23, 2024 suggests a price prediction of $80 for BEAM shares, giving the stock a ‘Buy’ rating. JP Morgan also rated the stock as ‘Overweight’.
Analysis of Beam Therapeutics Inc (BEAM)
Further, the quarter-over-quarter increase in sales is 0.81%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Beam Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -38.04% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.81, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 2.23M can be a very valuable indicator of volatility for BEAM stock. On a monthly basis, the volatility of the stock is set at 6.11%, whereas on a weekly basis, it is put at 4.58%, with a gain of 0.88% over the past seven days. Furthermore, long-term investors anticipate a median target price of $43.44, showing growth from the present price of $17.14, which can serve as yet another indication of whether BEAM is worth investing in or should be passed over.
How Do You Analyze Beam Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 10.88%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 88.04% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BEAM shares are owned by institutional investors to the tune of 88.04% at present.
